Gland Pharma in Focus After Fosun Stake Sale

Gland Pharma in Focus After Fosun Stake Sale Gland Pharma remains in focus after promoter Fosun Pharma Industrial sold around 6% stake in the company through block deals worth approximately ₹2,800 crore. The transaction has increased trading activity in the stock. The company has also reported strong Q1FY27 performance, with profit rising 47.9% year-on-year. Gland Pharma is expanding its CDMO business and plans investments aimed at increasing its presence in high-barrier pharmaceutical opportunities. Meanwhile, Gland Pharma recently received a positive USFDA inspection outcome for its Visakhapatnam facilities, while the company continues to engage with institutional investors through scheduled analyst meetings.